Inovio Offering Grosses $24.3M for DNA Vaccine Trials
By Tom Wall
Tuesday, January 25, 2011
Inovio Pharmaceuticals Inc. expects to gross $24.3 million in an offering of 21.1 million shares of common stock packaged with 10.5 million warrants priced at $1.15 a unit, 11.5 percent below the stock's closing price of $1.30 last Friday. The Blue Bell, Pa.-company said it expects to net $23 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.